Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $56.33.

Several brokerages recently commented on AGIO. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank lifted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th.

Agios Pharmaceuticals Stock Performance

AGIO opened at $35.22 on Monday. Agios Pharmaceuticals has a fifty-two week low of $26.66 and a fifty-two week high of $62.58. The company has a fifty day moving average of $34.29 and a two-hundred day moving average of $43.03. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of 3.11 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities research analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $39,000. Frazier Life Sciences Management L.P. lifted its stake in Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock worth $35,152,000 after acquiring an additional 25,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Agios Pharmaceuticals by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company’s stock worth $4,036,000 after acquiring an additional 9,606 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of Agios Pharmaceuticals by 2.1% in the 4th quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company’s stock valued at $6,588,000 after purchasing an additional 4,082 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at $5,337,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.